Stem Cell granted new Prolactin patents

Jul 08, 2008 (Datamonitor via COMTEX) -- SCTPF | Quote | Chart | News | PowerRating -- Stem Cell Therapeutics has received two new Prolactin corresponding patents that strengthen its intellectual property landscape through US and Australia.

According to the company, the patents cover the use of prolactin alone, as well as in combination with other therapeutics that augment recovery and therefore provide a broad base of protection. These are the first patents to issue in Prolactin patent family.

This intellectual property supports programs currently under development using prolactin alone or with anti-inflammatories to treat multiple sclerosis and using a combination of prolactin and EPO to treat other neurodegenerative diseases.

Alan Moore, President and CEO of Stem Cell, said: "We have the exclusive right to the use of prolactin for treating neurodegenerative diseases and therefore have a strong foundation to develop many possible products using prolactin, either as a single therapeutic or in combination with other neurogenic agents."

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index